Furthermore, the inability of subject NYSCT-02 to mobilize sufficient CD34+ PBSCs, as well as NYSCT-04 withdrawing prior to mobilization due to rapid disease progression, underscores the burden of both heavy pre-treatment chemotherapy and the inherent medical fragility of patients with relapsed/refractory sarcoma. This evidence concerns the gene CD34 and sarcoma.